REPL Replimune Group Inc.

13.97
+0.85  (+6%)
Previous Close 13.12
Open 13.25
Price To Book 3.21
Market Cap 442,341,903
Shares 31,663,701
Volume 37,489
Short Ratio
Av. Daily Volume 40,955

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 part of trial initiation announced June 1, 2019. Phase 1 data to be presented 4Q 2019.
RP1 and nivolumab
Solid tumors
Phase 2 trial to be initiated soon.
RP1 and cemiplimab
Cutaneous squamous cell carcinoma (CSCC)
Phase 1 trial to be initiated 3Q 2019.
RP2 and nivolumab
Solid tumors

Latest News

  1. Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
  2. Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
  3. Replimune to Present at Upcoming Investor Conferences
  4. Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  5. Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation
  6. Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019
  7. Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
  8. Replimune to Present at Two Upcoming Investor Conferences
  9. How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares?
  10. Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
  11. Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
  12. RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?
  13. Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  14. Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc
  15. Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update
  16. BMO Sees A Low-Risk Biotech Buy In Replimune